Alnylam Pharmaceuticals Studying the History of Genzyme Corporation Eyes Drug to Make Big Difference for Rare Disease

Bookmark and Share

Xconomy.com -- Alnylam Pharmaceuticals has a technology, RNA interference, that scientists say has potential to break new ground against hundreds of diseases for decades to come. But when you have a proverbial “platform” technology that can do so much, how exactly should you set priorities, and decide which drugs to develop first?

Back to news